Reduced tracheal stenosing effect of nintedanib in a patient with scarred posttraumatic tracheal stenosis and airflow limitation

<bold>Introduction:</bold> Nintedanib is a tyrosine kinase inhibitor and has been approved for the treatment of idiopathic pulmonary fibrosis (IPF) since 2020. In Clinical trials the antifibrotic effect of nintedanib was shown. Case A 60-year-old female medical assistant, infected with COVID-19 in 10/2020, experienced a complicated course of disease leading to tracheal stenosis. Various interventions, including stent placements and tracheal surgeries, were performed. Due to recurrent restenosis, the patient was treated with nintedanib, a tyrosine kinase inhibitor used in idiopathic pulmonary fibrosis. The treatment spanned 306 days, during which the patient showed stability in pulmonary function. Nintedanib demonstrated a potential anti-inflammatory effect, reducing the frequency of interventions and prolonging stent-free intervals. Despite one decrease in peak expiratory flow in 04/2023, the patient's condition remained stable. The results suggest nintedanib's efficacy in managing scar-related granulation tissue, highlighting its potential in treating tracheal stenosis. <bold>Conclusion:</bold> This case shows a decreased need for interventions and the longer duration of stent placement implies that nintedanib diminishes the severity of hypertrophic scarring by an anti-inflammatory effect. Based on our findings, it is advisable to explore this potential in additional clinical trials. <fig><object-id>erj;64/suppl_68/PA4777/F1</object-id><object-id>F1</object-id><object-id>F1</object-id><graphic></graphic></fig>